The purpose of cancer vaccines is to stimulate the body's natural defenses against cancer. The job of the vaccine is to "train" the immune system to identify and attack specific tumor peptides (a marker for tumor recognition). These peptide "tags" help the immune system find and attack cancer cells. There are three types of cells that can “see†and respond to these tags: T helper cells, cytotoxic T cells, and B cells, and the researchers believe that all three types of cells are “educated†or tolerated, ignoring cancer cell markers.
NEC (Japan Electric Co., Ltd.) is a Japanese company that provides information technology (IT) and networking products for commercial enterprises, communication services, and the government. It is the inventor of the Earth Simulator, the world's fastest supercomputer. However, in recent years, while IBM and Google have laid out the AI ​​field in a big way, Japanese technology companies that have accumulated decades of experience in artificial intelligence research and development have shown some low-key.
Soon, Japanese Prime Minister Shinzo Abe developed a new economic growth strategy for Japan. He urged Japanese companies to increase investment in new technologies and called for large-scale adoption of artificial intelligence and robots. In this context, Japanese technology companies have launched a new round of technical competition.
In recent years, NEC has increased its investment in artificial intelligence. In order to promote the development of artificial intelligence technology in the fields of Internet of Things, big data, security, etc., NEC launched the “NEC the WISE†artificial intelligence technology group brand in mid-2016. In the vertical application industry such as visualization, analysis, control and guidance, there are corresponding solutions. Among them, NEC has been ranked first or only in the industry in terms of sound recognition, image, image recognition, semantic analysis, mechanical learning, and prediction.
Katsumi Emura, Senior Vice President of NEC, said:
If we compete with Google on the same battlefield, we may not win, but in certain areas such as face recognition, we don't want to lose.
With IBM and Google scrambling to break into the traditional medical circle, NEC couldn't help it.
According to Lei Feng.com, on December 26, NEC announced the establishment of a new company to promote the development and application of peptide vaccines for cancer treatment through advanced artificial intelligence (AI) technology.
In recent years, with the further clarification of the human immune mechanism, life sciences have made great progress, and the treatment of cancer through the immune pathway has been developed as a new treatment. The clinical application of this method for peptide vaccines for treating cancer is currently under study.
The new company, called CYTLIMIC Ltd. (CYTLIMIC), aims to use NEC's WISE AI technology combined with machine learning and clinical trials to create a unique "immune function prediction technology" that is low-cost, short-lived Potentially potential polypeptide vaccines are discovered within.
In 2014, NEC and Yamaguchi University and Kochi University have started collaborative research and conducted clinical research with Yamaguchi University. They have discovered a peptide vaccine that can effectively treat liver cancer and esophageal cancer, and with about 85% of the Japanese population. Genetic information matching.
Currently, CYTLIMIC will also develop peptide vaccines into research-type preparations, confirm their safety and effectiveness through non-clinical and clinical trials, and explore commercialization with pharmaceutical companies to promote their use as new cancer drug applications. .
AI helps in the development of cancer vaccines and needs to do theseTumor antigen polypeptide is an important component of polypeptide vaccine. Tumor antigen must be degraded into short peptide in antigen-presenting cells (anTIgen presenTIng cell, APC) and form peptide-MHC-TCR complex to identify T cells and stimulate corresponding Cytotoxic T lymphocyte (CTL) response. The purpose of the polypeptide vaccine is to deliver a high dose of the tumor antigen polypeptide to the major histocompa TIb complex (MHC) molecule on the surface of the APC. Therefore, a suitable and effective tumor antigen polypeptide is very important for the preparation of the tumor vaccine. Tumor antigen polypeptides are MHC-restricted, and only the same peptide can be used in patients with the same MHC class I molecules, and certain tumor antigen peptides may induce immune tolerance rather than trigger an immune response due to tumor heterogeneity.
As can be seen from the above description, the development of a novel tumor vaccine requires finding a suitable and effective tumor antigen polypeptide that can universally match antigen presenting cells in a population and can trigger an immune response rather than induce immune tolerance.
Therefore, CYTLIMIC's vaccine development revolves around finding such peptide vaccines:
Discovered 50 billion amino acid sequence tumor antigens that can trigger immunity
Can universally match human leukocyte antigen (HLA)
Can be used as an immune adjuvant to enhance anti-tumor efficacy
We can follow customers' drawings or design to make Customized wire harness for various industries: game machine, ATM, POS machine, etc.
Customized wire assembly with AVL components from original manufactures. Also harness with local equivalent componets are workable with short L/T and competitive price, also flexible MOQ.
Related Products:cigarrete charging cable,custom audio cables,fiber optic cable,cigarrete lighter cable.
Cigarrete Lighter Cable,Custom Audio Cables,Fiber Optic Cable,High Quality Electrical Wire Harness,Automotive Wiring Harness,Coiled Cable,Wiring Assemblies,Fuse Holder,Auto Plug Cable,Cigarrete Charging Cable
ETOP WIREHARNESS LIMITED , https://www.etopwireharness.com